Sanofi
HealthcareNASDAQ:SNY · NASDAQ Global Select
+$0.18 today
Vol 1.17M · Avg 2.81M
Intrinsic Value
SNY Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
Intrinsic Value
System DCF · consensus of 4 models
Sign in to unlock intrinsic value
Free accounts get 5 valuations per week. Upgrade for more.
Monitor SNY
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price Alerts
Get notified when SNY drops below a target
Sign in to activate price alerts · unlock IV-based targets
Valuation History
Is SNY cheaper or more expensive than usual?
Review how the market has valued Sanofi over time before deciding whether today’s discount or premium is unusual.
Price History
Dividend-adjusted closing price
Change
-9.41%
Period High
$50.33
Period Low
$41.93
Latest
$44.28
Analyst Targets
See where analysts expect SNY to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street Price Targets
1-year price history with analyst consensus target
Current
$44.28
Low Target
$50.00
Avg Target
$51.00
High Target
$52.00
Upside (Avg)
+15.18%
Alternatives to SNY
Compare Sanofi with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$190.74B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.36B
Pfizer Inc.
NYSE:PFE
$149.07B
CVS Health Corporation
NYSE:CVS
$129.95B
Bristol-Myers Squibb Company
NYSE:BMY
$116.55B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.69B
GSK plc
NYSE:GSK
$106.55B
Medtronic plc
NYSE:MDT
$103.10B
HCA Healthcare, Inc.
NYSE:HCA
$85.76B
Bristol-Myers Squibb Company Ce
CELG-RI
$250.97M
Fundamental Analysis
Capture the investment case and test company quality
Write down the key idea, risks, and what would change your mind. Then review growth, profitability, returns, owner payouts, and insider activity.
My Notes
Journal entries for SNY
Sign in to keep notes
Track your buy/sell/hold decisions for every stock in your personal journal.
Quality Snapshot
Start with the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | -3.8% | -1.8% |
Revenue | N/A | N/A | -1.0% | +8.9% |
Equity | +2.6% | +4.2% | +5.2% | +9.2% |
Cash | N/A | N/A | +12.8% | +24.6% |
ROIC | 5.8% | 6.2% | 7.3% | 6.4% |
Analysis
Latest growth is strongest in Cash at +24.6% and weakest in EPS at -1.8%. Three-year average ROIC is 7.3%, which helps show whether that growth is being earned efficiently.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -3.8% | +8.9% (15yr)5 analysts |
| Revenue | N/A | N/A | -1.0% | +3.5% (15yr)7 analysts |
| Net Income | N/A | N/A | -4.3% | +8.4% (15yr)7 analysts |
| EBIT | N/A | N/A | -4.4% | +4.6% (15yr)7 analysts |
Analysis
Recent growth has been strongest in Revenue at -1.0% over three years. Forward estimates point to EPS at +8.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$47.4B of revenue converted into $7.6B of net income for the selected period. Gross margin is 72.1% and net margin is 16.4%, showing how much revenue survives after costs and taxes. EPS is $1.95, tying the income statement back to per-share earnings.
Capital Efficiency
Measure how well Sanofi turns capital into returns
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.9%
avg 9.7%
ROIC
7.7%
avg 6.2%
ROA
6.2%
avg 5.5%
Analysis
ROE is currently the strongest return metric at 10.9% versus its period average of 9.7%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Owner Returns
Review how cash comes back to shareholders
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
0.00%
Buyback Yield (TTM)
0.03%
Debt Paydown (TTM)
0.00%
Total Yield (TTM)
0.03%
Analysis
Total TTM shareholder yield is 0.03% including 0.00% from debt paydown. The largest current contributor is buybacks at 0.03%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Dividend Record
Check payout durability before counting on yield
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
5.38%
Annual Div/Share
$2.42
Payout Ratio
46.1%
Frequency
Annual
Shareholder Yield
10.39%
Next Ex-Date
Not announced
Next Payment
—
1Y Growth
+10.2%
3Y CAGR
+8.3%
5Y CAGR
+4.9%
Dividend Payments, Annual Total (TTM) & Yield
Analysis
The current indicated dividend yield is 5.38%, with TTM dividends of $2.42 per share. Three-year dividend growth is +8.3%, which helps show whether payouts are compounding or flattening. The payout ratio is 46.1%, so compare payout growth against earnings coverage. Payments are currently annual.
Company Overview
Understand how Sanofi makes money
Finish by grounding the numbers in the company profile, leadership, balance sheet, and free cash flow.
Key Information
Leadership
Put the business in management context
Company facts explain what Sanofi does; leadership context helps you judge who is responsible for capital allocation and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Belen Garijo Lopez | Chief Executive Officer & Director | $4.72M | — | 66 | — | — |
Olivier Charmeil | Executive Vice President of General Medicines | — | — | 63 | — | — |
Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | — | — | 69 | — | — |
Roy Papatheodorou | Executive Vice President & General Counsel | — | — | 48 | — | — |
Thomas Kudsk Larsen | Head of Investor Relations & General Medicines | — | — | 52 | — | — |
Thomas Triomphe | Executive Vice President of Vaccines | — | — | 52 | — | — |
Madeleine Roach | Executive Vice President & Head of Business Operations | — | — | 42 | — | — |
Natalie Bickford | Executive Vice President & Chief People Officer | — | — | 56 | — | — |
Fabrizio Gaudi | Head of Austrian, German & Swiss Operations | — | — | — | — | — |
Erik Wallström | Head of Therapeutic Area - Neurology Development | — | — | — | — | — |
François-Xavier Roger | Executive Vice President & Chief Financial Officer | — | — | 64 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $5.5B |
| Receivables | $482.0M |
| Inventory | $23.5B |
| Other Current | $635.0M |
| Total Current Assets | $30.2B |
| PP&E (Net) | $11.7B |
| Goodwill | $69.1B |
| Other Non-current | $17.1B |
| Total Non-current Assets | $97.9B |
| Total Assets | $128.0B |
Analysis
Selected assets total $128.0B for Latest. The largest visible component is Goodwill at $69.1B, about 54.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Finish by testing whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Explore More
Continue the stock analysis
Jump to another research area for this company.